Related Experiment Video
Updated: Feb 16, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities
Anteneh A Tesfaye1,2, Mandana Kamgar1,2, Asfar Azmi1,2
1a Department of Oncology, School of Medicine , Wayne State University , Detroit , MI , USA.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer related mortality in the United States in 2030, with a 5-year overall survival of less than 10% despite decades of extensive research. Pancreatic cancer is marked by the accumulation of complex molecular changes, complex tumor-stroma interaction, and an immunosuppressive tumor microenvironment. PDAC has proven to be resistant to many cytotoxic, targeted and immunologic treatment approaches. Areas covered: In this paper, we review the major areas of research in PDAC, with highlights on the challenges and areas of opportunity for personalized treatment approaches. Expert commentary: The focus of research in pancreatic cancer has moved away from developing conventional cytotoxic combinations. The marked advances in understanding the molecular biology of this disease especially in the areas of the microenvironment, metabolism, and DNA repair have opened new opportunities for developing novel treatment strategies. Improved understanding of molecular abnormalities allows the development of personalized treatment approaches.
Insights
Pancreatic cancer (PDAC) remains a deadly disease with poor survival rates. Advances in understanding its molecular biology offer new hope for developing personalized treatment strategies.
Area of Science:
- Oncology
- Cancer Research
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality with a low survival rate.
- PDAC is characterized by complex molecular alterations, tumor-stroma interactions, and an immunosuppressive microenvironment.
- Existing treatments show limited efficacy against PDAC due to its resistance.
Purpose of the Study:
- To review current research in PDAC.
- To highlight challenges and opportunities in developing personalized treatment approaches for PDAC.
- To discuss novel therapeutic strategies based on molecular understanding.
Main Methods:
- Literature review of major research areas in PDAC.
- Analysis of molecular biology, microenvironment, metabolism, and DNA repair in PDAC.
- Synthesis of findings to identify personalized treatment opportunities.
Main Results:
- Research focus has shifted from conventional cytotoxic therapies.
- Advances in understanding PDAC's molecular landscape are crucial.
- New therapeutic avenues are emerging from insights into microenvironment, metabolism, and DNA repair.
Conclusions:
- Personalized treatment approaches for PDAC are increasingly feasible.
- Targeting molecular abnormalities offers the most promising strategy for improving patient outcomes.
- Continued research into PDAC's complex biology is essential for therapeutic advancements.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:18Cancer